References
- Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–420.
- Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):615–626.
- Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665–686.
- Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician. 2007;75(10):1503–1508.
- Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leyomiomas. J Obstet Gynaecol Can. 2015;37(2):157–178.
- Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103(2):519–527.
- Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165–173.
- Fernandez H. [Ulipristal acetate and SPRM: a new entity for the therapeutic strategy for symptomatic myomas]. Gynecol Obstet Fertil Senol. 2018;46(10–11):671–672.
- Biscione A, Barra V, Bellone E, et al. Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis. Gynecol Endocrinol. 2020;36(1):87–92.
- European Medicines Agency. Esmya Article- 20 procedure-Esmya: new mesures to minimise risk of rare but serious liver injury; 2018 [accessed 2021 Jan 1]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/esmya.
- European Medicines Agency. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk; 2020 [accessed 2021 Jan 1]. https://www.ema.europa.eu/en/news/suspension-ulipristal-acetate-uterine-fibroids-during-ongoing-ema-review-liver-injury-risk.
- European Medicines Agency. Ulipristal acetate for uterine fibroids: EMA recommends restricting use; 2021 [accessed 2021 Jan 12]. https://www.ema.europa.eu/en/medicines/human/referrals/ulipristal-acetate-5mg-medicinal-products.
- Fernandez H, Schmidt T, Powell M, et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol. 2017;208:91–96.
- Spies JB, Coyne K, Guaou NG, et al. The UFS-QoL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99(2):290–300.
- European Medicines Agency. Esmya article-20 procedure-Annex-I-II-III; 2021 [accessed 2021 Jan 11]. https://www.ema.europa.eu/en/medicines/human/referrals/esmya.
- Munro MG, Critchley HOD, Fraser IS. The flexible FIGO classification concept for underlying causes of abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):391–399.
- Rozenberg S, Revercez P, Fastrez M, et al. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: unfortunate timing during the Covid-19 pandemic!!. Eur J Obstet Gynecol Reprod Biol. 2020;252:300–302.
- Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate ⋆. Fertil Steril. 2014;101(6):1565–1573.
- Powel M, Dutta D. Esmya® and the PEARL studies: a review. Womens Health (Lond). 2016;12(6):544–548.
- Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–432.
- Mas A, Tarazona M, Carrasco JD, et al. Updated approaches for management of uterine fibroids. Int J Womens Health. 2017;9:607–617.
- Singh SS, Belland L, Leyland N, et al. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. Am J Obstet Gynecol. 2018;218(6):563–572.
- Elsharoud A, Ali M, Al-Hendy A. Relugolix. GnRH (LHRH) receptor antagonist, treatment of uterine fibroids, treatment of endometriosis-related pain, treatment of prostate cancer. Drugs Fut. 2019;44(2):131–143.
- Rocca ML, Palumbo AR, Lico D, et al. Relugolix for the treatment of uterine fibroids. Expert Opin Pharmacother. 2020;21(14):1667–1674.